Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial
Guoying Liu(Thermo Fisher Scientific (United States)), Yan‐Qun Xiang(Sun Yat-sen University), Jianfei Li, Tian-Sheng Gao(Wuzhou Red Cross Hospital), Wei-Xin Bei(Sun Yat-sen University), Wang‐Zhong Li(Sun Yat-sen University), Changlong Chen(Sun Yat-sen University), Jinna Chen(Southern University of Science and Technology), Yao-Fei Jiang(Sun Yat-sen University), Wei‐Xiong Xia(Sun Yat-sen University), Shu-Hui Dong(Nanchang University), Nian Lu(Sun Yat-sen University), Herui Yao(Sun Yat-sen University), Jiahao Liu(Nantong University), Qin Liu(University of Science and Technology of China), Changqing Xie(Chinese Academy of Sciences), Yimin Liu(Sun Yat-sen University), Yan-Fang Ye(Sun Yat-sen University), Hu Liang(Sun Yat-sen University), Ya-Ting Hou, Liang-Ru Ke(Sun Yat-sen University), Yisheng Huang
Cited by 17
Related Papers
Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer
|Cell Research|2017|225
Dynamic Regulation of Estrogen Receptor-β Expression by DNA Methylation During Prostate Cancer Development and Metastasis
|American Journal Of Pathology|2004|202
The HIF-1α antisense long non-coding RNA drives a positive feedback loop of HIF-1α mediated transactivation and glycolysis
|Nature Communications|2021|196
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
|The Lancet Oncology|2023|195
Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer
|Nature Communications|2020|187